You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Xenon filed its NDA in September for U.S. commercialization of Zetucandler in focal seizures, moved the major depressive disorder readout to December, and reported a billion two in cash and cash into 2029.
Xenon Pharmaceuticals Inc. submitted azetukalner’s NDA for focal seizures to the U.S. Food & Drug Administration in September 2026. Net loss was $323.5 million for the nine months ended September 30, 2026, while cash and marketable securities totaled $1,153.5 million.
Xenon Pharmaceuticals Inc. submitted azetukalner’s drug application for focal seizures to the FDA in September 2026, reported $1.2 billion in cash, cash equivalents and marketable securities with cash runway into 2029, and expects X-NOVA2 results in December 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Xenon submitted the focal-seizure NDA, plans X-FIRST and additional epilepsy studies, moved X-NOVA2 data to December 2026, received positive Phase 1 support for pain Phase 2 studies planned for H1 2027, and ended the quarter with $1,153.5 million of cash and marketable securities and runway into 2029. Q3 net loss increased to $110.4 million, while neuropsychiatric adverse events prompted a voluntary enrollment pause in MDD and bipolar depression studies.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Direct external costs - Azetukalner | 55.76M | the three months ended June 30, 2026 filing | — |
| Direct external costs - Pain programs | 5.58M | the three months ended June 30, 2026 filing | — |
| Direct external costs - Pre-clinical, discovery and other programs | 4.68M | the three months ended June 30, 2026 filing | — |
| Indirect costs - Other unallocated expenses | 4.64M | the three months ended June 30, 2026 filing | — |
| Indirect costs - Personnel-related (including stock-based compensation) | 28.56M | the three months ended June 30, 2026 filing | — |
| Other G&A expenses | 2.69M | the three months ended June 30, 2026 filing | — |
| Personnel-related expenses (including stock-based compensation) - G&A | 15.91M | the three months ended June 30, 2026 filing | — |
| Professional and consulting fees - G&A | 5.34M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XENE
this stock
Xenon Pharmaceuticals Inc.
|
$3.98B | -9.7% | -82.8% | — | 7.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Xenon filed its NDA in September for U.S. commercialization of Zetucandler in focal seizures, moved the major depressive disorder readout to December, and reported a billion two in cash and cash into 2029.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XENE | +3.3% | +20.9% | -25.0% | +8.2% | -9.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.8% | +22.0% | -25.5% | +8.4% | -20.3% |
